XFP is the latest recombinant variant to be classified and incredibly it is the third of a recent set of recombinants with identical spike mutations. The earlier ones were XFJ and XFM.
I think of them as the "Doppelgängers".
#COVID19 #XFJ #XFM #XFP #Doppelgängers
🧵
Note "Doppelgänger" is not an agreed variant nickname, nor should it be. There doesn’t seem to be anything stopping other sets of variants or recombinants from ending up the same way, as multiple Doppelgänger packs.
🧵
Also note their non-Spike mutations do vary. But the Spike proteins of SARS-CoV-2 are the focus of much study and explain the success of most variants.
🧵
Here’s the growth shown by the 3 Doppelgängers (in this pack). XFM has the earliest detection, but it has not been successful.
XFJ was next and has grown quite strongly to over 2% globally.
XFP has shown even faster growth to over 1.5%.
🧵
XFM is a recombinant of LF.7.6.2 (descended from JN.1.16.1) and LS.2 (descended from JN.1.18.5).
The earliest XFM sample was reported from South Africa in December.
After a long gap, the remaining samples have mostly been from New York and alpine regions of France and Italy.
🧵
XFJ is a recombinant of LF.7.2 (descended from JN.1.16.1) and LS.2 (descended from JN.1.18.5).
The earliest XFJ sample was reported from Germany, in mid-March.
The samples reported have mostly been from Europe and the North-East US.
🧵
XFP is a recombinant of LF.7 (descended from JN.1.16.1) and LS.2 (descended from JN.1.18.5).
The earliest XFP sample was reported from Washington DC, in mid-March. Almost all the US samples detected since have been International Travellers arriving from India.
🧵
When India itself resumed sharing samples recently, XFP appeared to be dominant there from at least mid-April. So XFP is presumed to have originated in India, during the many months when there was no sample data shared.
🧵
The Doppelgängers offer a window into the historically unprecedented global variant generation engine we have constructed. I think of it as a flywheel, with tremendous momentum from the billions of infections and millions of chronic cases that are churning on year after year.
🧵
It’s not a totally random process, but I find it breathtaking to ponder the odds that 3 identical recombinations were produced in 3 separate places, 3 different ways, over just a few months.
🧵
There are ~1200 positions in the spike protein of SARS-CoV-2, each with ~20 possible letters, so ~24,000 possible combinations.
🧵
Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
Here's the latest variant picture for my new " Global - Other" report, to mid-May.
The NB.1.8.1 "Nimbus" variant is clearly dominant at 43%.
The XFG.* variant is another challenger, growing to 9%.
#COVID19 #GlobalOther #NB_1_8_1 #Nimbus #XFG
🧵
This perspective excludes all the high-volume countries and regions that I routinely report on: Australia, NZ, Europe, Canada and the US. The remaining countries are aggregated into this report.
🧵
For the "Global - Other" countries, the XFG.* variant is showing a marginal growth advantage of 0.4% per day (3% per week) over the NB.1.8.1 "Nimbus" variant. Any crossover looks distant.
🧵
Here's the latest variant picture for the United States, to early May.
The LP.8.1.* variant continued to fall, down to 35%.
The next challenger is XFG.*, which grew strongly to 19%.
#COVID19 #USA #LP_8_1 #XFG #NB_1_8_1 #Nimbus
🧵
For the US, the XFG.* variant shows a strong and accelerating growth advantage of 6.4% per day (45% per week) over LP.8.1.*, which now predicts a crossover in late-May (the data routinely lags).
🧵
XFG.* had mainly been reported from New York state, rising to 27% frequency. It has also been very common among the International Traveller samples. It rose in Vermont to 20%.
🧵
Here's the latest variant picture with a global scope, to mid-May.
The NB.1.8.1 "Nimbus" variant has grown strongly to take over dominance at 27%.
The LP.8.1.* variant has fallen to around 27%.
The XFG.* variant grew to 12%.
#COVID19 #Global #NB_1_8_1 #Nimbus #LP_8_1 #XFG
🧵
Following the declaration by the WHO of NB.1.8.1 as a Variant Under Monitoring and as Nextstrain Clade 25B, I have separated that variant and its descendants into a new “L2” group, shown in Sky Blue.
🧵
Globally, the NB.1.8.1 "Nimbus" variant is showing a strong growth advantage of 6.3% per day (44% per week) over the LP.8.1.* variant, with a crossover in mid- May.
🧵
Reported Cases have continued to rise sharply at the national level and in most states & territories, with the 7-day average doubling in the last 2 weeks.
#COVID19 #Australia
🧵
The last time 800 cases/day were reported nationally was in late January, on the downslope of the XEC wave. The peak of this wave has not been reached.
As always, it is hard to be certain with this series; the data quality is very shoddy and the raw data is incredibly spiky.
🧵
Reported cases are continuing to grow strongly in NSW, with the Reff (case momentum) fairly steady between 1.2 and 1.3, so sustained exponential growth.
The prior wave (XEC in January) in NSW peaked at around 410/day, which looks within reach for this wave.
🧵
My work was used in a recent piece for The Conversation: "There’s a new COVID variant driving up infections. A virologist explains what to know about NB.1.8.1".
The links in the paragraph starting "Genomic sequencing has confirmed NB.1.8.1 …" point to my report for Australia, from my regular variant analysis. I update that and my similar reports for other countries and regions weekly.
🧵
I didn’t get named as a contributor, which is a little disappointing, but seems to be typical for this outlet. IAC it’s good to see my work is useful.
🧵